I haven't contributed for some time and was on the list under a
different yahoo address which I no longer have.

I have what I consider some great news regarding the treatment of my
Peripheral Neuropathy (PN). Here's the story: Back in December 05
I filled my last prescription for Wellbutrin, I also stopped drinking
on December 28th. I decided to stop the anti-depressants and try
SamE approximately the third week of January 06. The SamE seemed to
help with depression about as much as the Wellbutrin, so I was
content with the change. When I stopped I had 10 300mg XL's left
and kept them. A week ago I was feeling really down about the pain
and mobility issues and decided to start the Wellbutrin again to help
with depression. Within two days I noticed the pain in my feet
subsided significantly and it continues to be manageable to the point
where I no longer feel much pain at rest and only a little when
active. It also seems that the proprioception issues are somewhat
better. I started to put two and two together and realized that my
neuropathy did not bother me much before I quit drinking and taking
Wellbutrin. I couldn't figure out why it was getting worse as I was
abstinent and felt that alcohol may be the primary factor in my
disease. I thought perhaps the alcohol had been masking some of the
pain.

Yesterday, I researched wellbutrin on the Internet and sure enough it
has been used successfully for some in the treatment of the symptoms
of PN. I thought I had done thorough research but obviously not.
So, I'm am really kind of excited about this as Wellbutrin is a drug
I have no negative side effects from and in fact, helps me reduce my
smoking, curbs my appetite and helps with my mental state. My God,
almost an all purpose pill!!

I hope this moderate success continues, I thought others might be
interested and I would be interested to hear if any have tried
Wellbutrin? It is a dopamine and norepinephrine uptake inhibitor,
whereas Cymbalta (which I have not tried) is a serotonin and
norepinehrine uptake inhibitor. Cheers, Ken